These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10477157)

  • 1. An indistinct balance: the safety and efficacy of parenteral iron therapy.
    Besarab A; Frinak S; Yee J
    J Am Soc Nephrol; 1999 Sep; 10(9):2029-43. PubMed ID: 10477157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy.
    Eschbach JW; Adamson JW
    Kidney Int Suppl; 1999 Mar; 69():S35-43. PubMed ID: 10084284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for iron supplementation: oral versus intravenous.
    Macdougall IC
    Kidney Int Suppl; 1999 Mar; 69():S61-6. PubMed ID: 10084288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
    Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
    Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron metabolism and iron substitution during erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Clin Investig; 1994; 72(6 Suppl):S11-5. PubMed ID: 7950165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutritional implications of recombinant human erythropoietin therapy in renal disease.
    Sanders HN; Rabb HA; Bittle P; Ramirez G
    J Am Diet Assoc; 1994 Sep; 94(9):1023-9. PubMed ID: 8071484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron status and iron supplementation in peritoneal dialysis patients.
    Vychytil A; Haag-Weber M
    Kidney Int Suppl; 1999 Mar; 69():S71-8. PubMed ID: 10084290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
    Wingard RL; Parker RA; Ismail N; Hakim RM
    Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
    Glaspy J; Cavill I
    Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy.
    Van Wyck DB
    Nephrol Dial Transplant; 2000; 15 Suppl 3():36-9. PubMed ID: 11032356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
    Lin CL; Hsu PY; Yang HY; Huang CC
    Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
    Eschbach JW; Abdulhadi MH; Browne JK; Delano BG; Downing MR; Egrie JC; Evans RW; Friedman EA; Graber SE; Haley NR
    Ann Intern Med; 1989 Dec; 111(12):992-1000. PubMed ID: 2688507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.